ProPhase Labs enters $7.73M equity line with Keystone Capital; issues 352,176 commitment shares

ProPhase Labs, Inc.

Up to $7,730,973 of common stock may be sold to Keystone Capital at 90% of lowest traded price or VWAP.
Commitment fee: 352,176 shares issued to investor as consideration for the purchase commitment.
Use of proceeds: working capital and general corporate purposes; 30% to redeem preferred stock if issued.
Each fixed purchase limited to lower of 100,000 shares or $100,000; VWAP purchases capped at $5M aggregate.
Investor prohibited from short sales or hedging during term; company retains termination right upon one day notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.